PPD in the News
PPD doubles down on Science 37 collab for siteless trial push
PPD and Science 37 announced an innovative collaboration in which PPD will be fully enabled to design, build, test, implement and execute digital trials using Science 37's DCT platform.
Optimizing clinical trial decision-making
Ravi Ramachandran discusses the need for technologies that accommodate trial participants to obtain a more holistic view of their condition during the clinical research process.
Stability testing of protein therapeutics using dynamic light scattering
John Bak and Eric Olson explain how dynamic light scattering presents a good analytical technique for testing protein stability.
PPD, Clinical Ink join on lupus assessment and endpoint data
Carol Olson comments on how the two companies have partnered to develop a systemic lupus erythematosus assessment review to streamline clinical trials.
Bacterial endotoxins testing of water-insoluble drug substances by means of dispersion with dimethyl sulfoxide
The authors demonstrate a technique for sample preparation in which the drug substance is dissolved in dimethyl sulfoxide, followed by dilution in water.
US Army taps PPD to conduct PTSD treatment research
PPD receives five-year award to test the effectiveness and safety of pharmacotherapeutic drug candidates for the treatment of PTSD in U.S. military active duty personnel and veterans.
PPD pens Clinical Ink collab for new lupus trial platform
The companies jointly developed a systemic lupus erythematosus (SLE) assessment review process to simplify operationalizing clinical trials for the chronic autoimmune disease.
Advantages of developing and deploying an in-house regulatory intelligence
Sean Schofield, William Waggoner and John Joines write about the processes and considerations for developing and maintaining an in-house regulatory intelligence database.
Special report on clinical trials: Delving into decentralization
In this report, Niklas Morton notes how when a fully decentralized trial is not feasible, a hybrid design still offers organizations opportunities to minimize—if not eliminate—burdens on patients.